Is This the Right Time to Hold Labcorp Stock in Your Portfolio?

LH eyes growth via specialty test expansion, acquisitions and LaunchPad savings, but currency headwinds and macro pressures cloud the outlook.
Fierce Biotech

Labcorp, PathAI expand partnership to offer AI tech for digital pathology diagnostics

Labcorp expanded its partnership with PathAI to offer its FDA-cleared digital pathology platform at the life science giant’s U.S. network of anatomical pathology labs and participating hospitals.

Labcorp: Q4 Earnings Snapshot

(LH) on Tuesday reported fourth-quarter profit of $164.7 million. The Burlington, North Carolina-based company said it had ...

Labcorp expands PathAI pact to roll out digital pathology platform in US

Labcorp’s pathologists will use the software to review, interpret and manage digital images of slides for primary diagnosis.
TMCnet

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx 1, an FDA-cleared digital pathology ...

A Look At Labcorp (LH) Valuation After Recent Share Price Strength

Labcorp Holdings (LH) continues to attract attention after recent share price moves, with the stock last closing at $289.12. Investors are weighing this level against the company’s fundamentals in ...